Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome.
Bhaskar ST, Patel VG, Porter DL, Schuster SJ, Nastoupil LJ, Perales MA, Tomas AA, Bishop MR, McGuirk JP, Maziarz RT, Chen AI, Bachanova V, Maakaron JE, Riedell PA, Oluwole OO. Bhaskar ST, et al. Among authors: maakaron je. Blood Adv. 2023 Sep 12;7(17):4765-4772. doi: 10.1182/bloodadvances.2022008937. Blood Adv. 2023. PMID: 36508286 Free PMC article.
Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
Jurdi NE, Hoover A, O'Leary D, Cao Q, Gupta A, Ebens C, Maakaron JE, Betts BC, Rashidi A, Juckett MB, Lund T, Bachanova V, MacMillan ML, Miller JS, Orchard PJ, Wagner JE, Vercellotti G, Weisdorf DJ, Dusenbery K, Terezakis S, Holtan SG. Jurdi NE, et al. Among authors: maakaron je. Transplant Cell Ther. 2023 Sep;29(9):576.e1-576.e5. doi: 10.1016/j.jtct.2023.06.008. Epub 2023 Jun 11. Transplant Cell Ther. 2023. PMID: 37311510 Clinical Trial.
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
Scordo M, Flynn JR, Gonen M, Devlin SM, Parascondola A, Tomas AA, Shouval R, Brower J, Porter DL, Schuster SJ, Bachanova V, Maakaron J, Maziarz RT, Chen AI, Nastoupil LJ, McGuirk JP, Oluwole OO, Ip A, Leslie LA, Bishop MR, Riedell PA, Perales MA. Scordo M, et al. Among authors: maakaron j. Blood Adv. 2023 Sep 26;7(18):5579-5585. doi: 10.1182/bloodadvances.2023010302. Blood Adv. 2023. PMID: 37522731 Free PMC article.
Age is No Barrier: CAR-T Therapy in Older Adults.
Maakaron JE, William BM. Maakaron JE, et al. Drugs Aging. 2023 Aug;40(8):685-689. doi: 10.1007/s40266-023-01047-z. Epub 2023 Jul 11. Drugs Aging. 2023. PMID: 37432595 Review.
Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host Disease.
Holtan SG, Hoeschen A, Cao Q, Ustun C, Betts BC, Jurdi NE, Maakaron J, Rashidi A, Miller JS, Wagner JE, Blazar BR, Jacobson PA, Panoskaltsis-Mortari A, Weisdorf DJ, MacMillan ML. Holtan SG, et al. Among authors: maakaron j. Transplant Cell Ther. 2023 Aug;29(8):509.e1-509.e8. doi: 10.1016/j.jtct.2023.05.021. Epub 2023 Jun 4. Transplant Cell Ther. 2023. PMID: 37279855 Free PMC article. Clinical Trial.
Validation of Nivestym compared to Neupogen: An NMDP analysis.
Maakaron J, Picotte K, Tram K, Bakken R, Oakes J, Cody M, Miller J, Devine SM, Stefanski HE. Maakaron J, et al. J Clin Apher. 2024 Feb;39(1):e22097. doi: 10.1002/jca.22097. Epub 2023 Dec 1. J Clin Apher. 2024. PMID: 38037757 No abstract available.
50 results